BrainStorm Cell Therapeutics
– Resource consumption will be reduced by 50% to accelerate ALS development – Plans underway for registrational Phase 3b U.S. clinical trial for NurOwn in ALS NEW YORK, Oct. 24,…
– Resource consumption will be reduced by 50% to accelerate ALS development – Plans underway for registrational Phase 3b U.S. clinical trial for NurOwn in ALS NEW YORK, Oct. 24,…